Celiac disease market and epidemiology analysis 2018-2034 with detailed profiles of marketed and pipeline drugs, including kan-101 (kanyos bio) and timp-glia/tak 101 (takeda)

Dublin, june 07, 2024 (globe newswire) -- the "celiac disease market: epidemiology, industry trends, share, size, growth, opportunity, and forecast 2024-2034" report has been added to researchandmarkets.com's offering. the 7 major celiac disease markets reached a value of us$ 584.9 million in 2023. looking forward, the 7mm are expected to reach us$ 1,362.1 million by 2034, exhibiting a growth rate (cagr) of 9.85% during 2023-2034. the increasing incidences of inherited chromosomal disorders on account of gene mutations, mainly hla-dq2 and hla-dq8, are primarily driving the celiac disease market. in addition to this, the rising prevalence of several associated risk factors, such as gastrointestinal infections, type 1 diabetes, autoimmune thyroid disease, alterations in the composition and diversity of gut bacteria, etc., is creating a positive outlook for the market. moreover, the easy utilization of enzyme supplements, including lactase and alpha-galactosidase, to improve digestion and reduce symptoms of bloating and gas is also propelling the market growth.
TAK Ratings Summary
TAK Quant Ranking